

AstraZeneca (AZ), along with its global biologics research and development arm, MedImmune, will demonstrate how it is rapidly delivering on the Company's science-led strategy for transformational cancer medicine development at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 2-6 June 2017.

With **three new oncology medicines addressing the unmet needs** of patients with ovarian, lung, and bladder cancers approved in under three years, AZ is now **halfway to delivering on its promise to launch six new medicines for cancer by 2020**. This progress is reflected in the **100 company-sponsored and supported abstracts, including five Best-of-ASCO presentations, 11 oral presentations and eight poster discussions**, accepted for the meeting. These include new data on approved and potential new medicines from the Company's pipeline across multiple scientific platforms and tumour types.

Key Trial Readouts

Lynparza	<ul style="list-style-type: none"> 'Late-breaker' data from the OlympiAD trial of Lynparza (olaparib) versus chemotherapy in BRCA-mutated metastatic breast cancer (Abstract #LBA4) are the first positive Phase III results beyond ovarian cancer. Additional Lynparza data will include: <ul style="list-style-type: none"> ➤ SOLO-2: Oral presentation of Phase III data on the relationship between HRQOL and patient-centred and clinical outcomes with Lynparza maintenance following chemotherapy BRCA+ platinum-sensitive relapsed serous ovarian cancer (Abstract #5507) ➤ Study 19: Randomized Phase II overall survival and updated progression-free survival data for the combination of Lynparza and cediranib versus Lynparza alone in recurrent platinum-sensitive ovarian cancer (Abstract #5535)
AZD1775	<ul style="list-style-type: none"> Phase I data on the WEE1 inhibitor, AZD1775+ radiation + temozolomide in newly-diagnosed GBM and evaluation of intratumoural drug distribution in patients with recurrent GBM (Abstract #2005) Phase I trial of AZD1775 in combination with neoadjuvant weekly cisplatin and docetaxel in borderline-resectable head and neck squamous cell carcinoma (HNSCC) (Abstract #6034)
Tagrisso (osimertinib)	<ul style="list-style-type: none"> Extended evidence of osimertinib's effect on CNS metastases <ul style="list-style-type: none"> ➤ An oral presentation will provide further evidence of the response to treatment in EGFR T790M+ NSCLC and CNS metastases (Abstract #9005). ➤ Ability of Tagrisso to cross the blood-brain barrier will be provided through updated results from the BLOOM trial of Tagrisso in patients with EGFR+ NSCLC and leptomeningeal disease (Abstract #2020).
Imfinzi (durvalumab)	<ul style="list-style-type: none"> New data on Imfinzi (durvalumab) as monotherapy and in combination <ul style="list-style-type: none"> ➤ Updated data from the NSCLC and bladder cancer cohorts of the Phase I/II Study 1108 of durvalumab in patients with advanced solid tumours. New data in locally-advanced or metastatic urothelial carcinoma (mUC) (Abstract #4525) ➤ Updated monotherapy Study 1108 results in Stage IIIB/IV NSCLC (Abstract #9085) will also be presented. In an oral presentation, MedImmune will present data on a novel relationship in NSCLC between EGFR pathway activation and the immunosuppressive molecule CD73 (Abstract #11505).
DNA Damage Response	<ul style="list-style-type: none"> OlympiAD: Phase III trial of olaparib monotherapy versus chemo HER2-negative mBC and a germline BRCA mutation (gBRCAm). (Abstract LBA4) HRQOL and patient-centered outcomes with maintenance olaparib vs. placebo following chemo in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial. (Abstract5507) Overall survival and updated progression free survival results from a randomized Phase II trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum sensitive ovarian cancer (Abstract 5535) A phase 1 clinical trial of AZD1775 in combination with Neoadjuvant weekly Cisplatin and Docetaxel in borderline resectable SCCHN (Abstract 6034)
Tumor drivers and Resistance	<ul style="list-style-type: none"> CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3)(Abstract 9005) Updated BLOOM results: osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR+NSCLC (Abstract 2020)
I/O	<ul style="list-style-type: none"> Updated efficacy and tolerability of durvalumab in advanced UC (Abstract4525) Updated safety and Clinical activity of Durvalumab monotherapy in pre-treated stage IIIB/IV NSCLC (Abstract 9085) Increased CD73 and reduced IFNG signature expression in relation to response rates to anti-PD-1(L1) therapies in EGFR-mutant NSCLC (Abstract11505)

CORPORATE COMMUNICATIONS



"2017 is a pivotal year for our oncology portfolio as global launch and development programmes for Lynparza, Tagrisso and Imfinzi® gain momentum, with further pivotal data anticipated in the coming months, in particular in 1st-line NSCLC. We are excited to demonstrate the strength of our rapidly-expanding portfolio at ASCO, including the positive OlympiAD results for Lynparza® in BRCA-mutated metastatic breast cancer." said Jamie Freedman, Executive Vice President, Oncology at AstraZeneca